Hims & Hers has appointed Kathryn Beiser as chief communications officer, reporting directly to CEO Andrew Dudum. Beiser joins from Eli Lilly, where she spent five years as CCO leading communications for its GLP-1 obesity drug franchise, and previously held senior roles at Kaiser Permanente and Hilton Worldwide.

The company recorded $2.35 billion in revenue for 2025, a 59% year-over-year increase, driven by expanded telehealth services and prescription shipments. EBITDA reached $318 million and operating cash flow stood at $300 million, supported by a subscriber base exceeding 2.5 million and an average monthly revenue per user of $83.

Hims & Hers replaced compounded GLP-1 offerings with branded Wegovy and Ozempic distribution under its partnership with Novo Nordisk. This agreement removes previous legal uncertainties and integrates a proven obesity treatment line into its platform, strengthening its positioning in the profitable weight-loss market.

Following the Novo Nordisk deal, Barclays raised its price target on Hims & Hers shares from $25 to $29 and maintained an Overweight rating. The firm cited underappreciated market opportunity from new product rollouts and projected further upside as the company scales branded prescription therapies.